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Pre-existing neutralizing antibody (NAb) against adeno-asso-
ciated virus (AAV) commonly found in primates is a major
host barrier that can severely compromise in vivo gene transfer
by AAV vectors. To achieve proof-of-concept success in clinical
development of recombinant AAV (rAAV)-based in vivo gene
therapy, it is crucial to consider the potential interference of
NAb and to enroll serologically compatible study subjects. In
this study, we report a large AAVNAb dataset comprising mul-
tiple large animal species and AAV serotypes and compare two
NAb assays based on in vitro or in vivo transduction inhibition,
respectively. Together with previously published AAV seroepi-
demiology studies, these data can serve as a reference for select-
ing suitable serotypes, study subjects of large animal species,
and potentially human patients for rAAV treatment. In addi-
tion, we modeled the intrathalamus rAAV9 delivery in the
presence of circulating anti-AAV9 NAb generated by either
pre-immunization or passive transfer of NAb-positive large an-
imal serum to mice. The data showed that circulating NAbmay
not be the sole determinant to inhibit brain transduction.
Other aspects of pre-existing AAV immunity following natural
infection or rAAV administration may be further studied to
establish a more accurate inclusion criterion for clinical studies
employing intraparenchymal rAAV9 injections.
INTRODUCTION
Recombinant adeno-associated viruses (rAAVs) have been widely
used as in vivo gene transfer vectors and extensively tested in various
gene therapy applications. Translational studies revealed that,
following in vivo delivery of rAAVs, the complex interactions be-
tween rAAV and the primate immune system represent a major hur-
dle toward efﬁcacious and sustainable in vivo gene transfer.1–3
In humans, pre-existing neutralizing antibody (NAb) against assem-
bled AAV capsid in the circulation is the ﬁrst immunological barrier
that can potentially compromise or abrogate transduction.4 Unfortu-
nately, NAbs against AAV are widespread in general human popula-
tions.5 The presence of NAb is believed to stem frommother-to-child
transmission and from natural AAV infection during childhood.6 The
inﬂuence of NAb on rAAV-mediated in vivo gene delivery depends
on several factors, such as route of administration, target tissue,
NAb titer, and rAAV dose. Delivery to the bloodstream is most sus-
ceptible to NAb;7,8 immune-privileged organs such as the brain and
eyes are more resistant to NAb;9 NAb of a higher titer has a more pro-
found inhibitory effect on transduction;10 increasing the rAAV dose
can overcome NAb to some extent.11 In addition to humans, non-hu-
man primates (NHPs) are also natural hosts of AAV and therefore
commonly possess AAV NAbs that interfere with rAAV-mediated
translational gene therapy studies and basic research.
To circumvent the inhibitory effect of NAb, many approaches have
been developed and demonstrated proof-of-concept efﬁcacy, such
as plasmapheresis12,13 and using empty capsid decoys.14 However,
these methods generally are not effective in tackling high-NAb titers,
and their clinical impact on gene therapy is yet to be established. The
simplest and most effective workaround is to screen subjects for AAV
NAb and recruit suitable ones in a trial. Although it excludes a
substantial number of patients from a clinical study, the enrollment
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criterion based on NAb titer is essential to demonstrate the efﬁcacy
of gene therapy for hemophilia B.15,16 Currently, screening for NAb
against the AAV serotype to be used in a gene-therapy study
involving human subjects or large animals remains a common and
effective practice. Therefore, accurate determination of the AAV
NAb in study subjects is key to many rAAV gene transfer studies.
AAV NAb present in body ﬂuid is usually determined by an in vitro
transduction inhibition assay.5,17 In this assay, a body ﬂuid sample
such as serum is serially diluted; each diluted sample is incubated
with a certain serotype of rAAV expressing a reporter to allow for
NAb-rAAV binding. Then the mixture is used to infect cell culture
followed by the measurement of reporter expression as a gauge of
transduction efﬁciency. The presence of NAb will inhibit transduc-
tion up to a certain dilution factor compared to proper controls.
The titer of NAb can be deﬁned as the lowest dilution factor that in-
hibits transduction by more than 50% or between this lowest dilution
factor and the next one (e.g., this study). Alternatively, the dilution
factor that inhibits transduction by 50% can be calculated by logistic
regression and deﬁned as the NAb titer. It should be noted that the
in vitro AAV NAb assay involves several variables that are not stan-
dardized among different laboratories, such as incubation and culture
conditions, reporter choice, cell type, and MOI. In addition, the re-
porter rAAVs are usually produced in-house and therefore subject
to variations. Nevertheless, studies have shown that the assay remains
robust and is resistant to some variables.18 At our facility, we have
been using a standard operating procedure to perform in vitro NAb
assays since 2008. A recent study showed that the NAb results ob-
tained from our laboratory and another laboratory using a different
protocol are highly consistent.19
An intrinsic limitation of the in vitro AAV NAb assay is the low
sensitivity, due in part to the generally inefﬁcient cell culture trans-
duction by rAAVs. Therefore, a high MOI of reporter rAAV has to
be used in the assay, which may artiﬁcially overcome the inhibitory
effect of low-titer NAb and make a false-negative call. This caveat is
especially important in scenarios that are prone to the inhibition by
even low-titer NAb, such as systemic delivery to target the liver.
To more closely mimic the neutralizing effect of NAb on in vivo
rAAV transduction, an adoptive transfer method to detect NAb
was developed.7,10 In this assay, mice are pre-conditioned by
receiving IV injection of a test sample, such as intravenous immuno-
globulin (IVIg) or serum, followed by a second injection of a certain
serotype of rAAV expressing a secretory reporter. The in vivo trans-
duction is measured by quantifying reporter expression in the serum
and compared to proper controls. Due to the high in vivo transduc-
tion capability of rAAV, a low dose of reporter rAAV is sufﬁcient to
yield robust expression and therefore allows for the detection of low-
titer NAbs, i.e., at a higher sensitivity. The in vivo NAb assay was em-
ployed to screen for AAV8 sero-negative patients of hemophilia B
and proved to be essential for the success of the gene therapy
trial.15,16 However, the in vivo NAb assay is far more cumbersome
than the in vitro assay, especially when a large number of samples
need to be screened.
Circulating AAV NAb may also compromise transduction in the
brain and eyes following a direct rAAV injection into these im-
mune-privileged compartments.20–22 Previous studies revealed that
such an inhibitory effect depends on several factors, such as the sero-
type,23 NAb titer,24,25 and route of administration.21 Early studies
mainly focused on AAV2 and AAV5 when evaluating the impact of
circulating AAV NAb on brain transduction by a direct intraparen-
chymal injection. More recently, AAV9 and AAVrh.10 have been
shown to more efﬁciently target CNS cells by a direct brain injection
and therefore are suitable for gene therapy development for a range of
CNS diseases such as Parkinson’s disease and lysosomal diseases with
CNS involvement.26,27
Here, we report a survey of circulating AAV NAbs in six different
species of large animals that are commonly used in pre-clinical
gene therapy development. In particular, the high-throughput
in vitro NAb assay allowed us to analyze a large number of rhesus
macaques (RMs) and cynomolgus macaques (CMs) and to test for
multiple AAV serotypes. In addition, we also conducted in vivo
NAb assay with a subset of serum samples, which showed higher
sensitivity than the in vitro assay with the exceptions of some animal
species. Lastly, we found that the circulating anti-AAV9 NAb up to
1:20–1:40 alone may not be sufﬁcient to inhibit Th injection of
rAAV9 in mice. Together, these results shed more light on screening
and selecting suitable study subjects of large animal species and
potentially humans for rAAV-mediated gene therapy.
RESULTS
Survey of AAV NAbs in Large Animals
During the past few years, we performed an in vitro AAV NAb assay
according to a standard operating procedure with serum samples
from various large animal species, including RM, CM, marmoset,
chimpanzee, dog, and sheep, generating a total of 2,555 assay data
points. These serum samples were collected from naive animals
that were screened for NAb titer for various purposes. In most cases,
animals were screened to identify the ones with non-detectable or low
levels of NAb for pre-clinical rAAV gene-therapy studies.
The results are summarized and presented in Figure 1. RM and CM
account for the vast majority of donor animals (1,632 and 790 data
points, respectively), reﬂecting their common use in translational
gene therapy development. NAbs against a series of clinically relevant
AAV serotypes were tested, including AAV1, 2, 3B, 5, 6, 8, 9, DJ, DJ8,
rh.8, and rh.10, among which AAV1, 8, 9, rh.10 were most often
tested. Anti-AAV1 NAb shows low prevalence in both RM and
CM; sero-negative samples account for 55% and 57% in these species,
respectively. Similarly, anti-AAV9 NAb shows low prevalence or
tends to display low titer of less than 1:10 in these species. In contrast,
both RM and CM tend to have high anti-AAV8 NAb titers of more
than 1:10. Anti-AAVrh.10 NAb appears more prevalent in CM
than in RM, mainly due to more CM samples containing titers of
more than 1:20. Notably, RM samples have widespread anti-AAV2
NAb with only 1.3% sero-negative, but low prevalence of anti-
AAV3B and AAV5 NAbs with more than 50% sero-negative despite
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small sample sizes. This NAb proﬁle is similar to that of human pop-
ulations previously reported.28 The sample sizes and serotypes tested
for the other species are limited (Figure 1C). However, anti-AAV9
and rh.10 NAbs appear common in marmoset, dog, and sheep, but
the titers are generally lower in marmoset than the other two species.
Taken together, the survey of anti-AAV NAbs comprises several
large-animal species and AAV serotypes with a large sample size in
many cases. For RM and CM, two NHP species commonly used in
translational gene therapy studies, they tend to have low prevalence
and/or low titer of anti-AAV1 and AAV9 NAbs; the opposite is
observed for anti-AAV8 NAb.
Correlation between In Vitro and In Vivo AAV NAb Assays
For a subset of serum samples that we tested by the in vitroNAb assay,
we also performed an in vivo NAb assay that is based on adoptive
transfer of serum sample to wild-type (WT) mice, and quantiﬁcation
of its inhibitory effect on in vivo transduction by rAAV of a
certain serotype expressing human alpha 1-antitrypsin (hA1AT) as
a secretory reporter. The hA1AT in the recipient mouse serum
can be quantitatively measured to gauge transduction efﬁciency.
The experimental workﬂow is illustrated in Figure 2A and detailed
in the Materials and Methods.
Most samples tested in the in vivo NAb assay were sero-negative in
the in vitroNAb assay (titer < 1:5) (Figure 2B), because the main pur-
pose of performing the in vivo NAb assay was to identify the samples
with a low NAb titer that was not detectable in the less-sensitive
in vitroNAb assay. As expected, a small fraction of sero-negative sam-
ples determined by the in vitro NAb assay were able to signiﬁcantly
inhibit rAAV.hA1AT transduction in mice. In contrast, the majority
of samples showing a high titer of more than 1:10 in the in vitro NAb
assay were able to signiﬁcantly inhibit rAAV.hA1AT transduction
in mice (Figure 2B). Interestingly, almost all serum samples from
marmoset and sheep were not able to inhibit in vivo transduction
despite their NAb titers of more than 1:5 in the in vitro NAb assay
(Figure 2C).
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Figure 1. Survey of AAV NAbs in Large Animals
Stacked histogram showing the distribution of (A) rhesus macaque, (B) cynomolgus
macaque, (C) marmoset, chimpanzee, dog, and sheep serum samples harboring
different levels of AAV NAbs as determined by an in vitro transduction inhibition
assay (seeMaterials andMethods for assay details). Samples are categorized by the
AAV NAb titer that is presented on a gray scale. Each stacked bar represents the
test results for an individual AAV serotype. The AAV serotype, number of animals
tested for each serotype (N), and percentage of NAb-negative samples (Neg%;
defined as NAb titer <1:5) are labeled for each bar.
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(A) Experimental workflow of the in vivo NAb assay (see Materials and Methods for
assay details). (B and C) Dot plot of serum samples tested by both the in vitro and
in vivo assays. Each dot represents the serum sample from an individual large
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Overall, we found good correlation between the in vitro and in vivo
NAb assays; most sero-negative samples determined by the in vitro
assay did not signiﬁcantly inhibit in vivo rAAV transduction, whereas
most sero-positive samples determined by the in vitro assay did. The
in vivo assay was able to identify the inhibitory sera that presumably
contain an anti-AAV NAb titer below the detection limit of the
in vitro assay (1:5 in this study).
Pre-immunization with rAAV9 by IM Injection in Mice
Compromises CNS Transduction by Brain rAAV9 Delivery
To model the effect of circulating NAb on direct brain gene delivery
by rAAV9, we ﬁrst pre-immunized mice with an AAV9 vector ex-
pressing EGFP (scAAV9.EGFP) by either Th injection or intramus-
cular (IM) injection. Four weeks later, anti-AAV9 NAb in the sera
was determined by the in vitro NAb assay (Figures 3A and 3B). IM
injection led to robust NAb formation of more than 1:20 in all mice
(n = 6). In contrast, only one mouse receiving Th injection showed
detectable NAb (n = 6). As expected, naive mice receiving no rAAV
treatment were sero-negative (n = 4). Five weeks after the ﬁrst injec-
tion, all mice received Th injection of an AAV9 vector expressing
ﬁreﬂy luciferase (rAAV9.Fluc). For the mice that received the ﬁrst
Th injection, the second Th injection was performed at the contra-
lateral hemisphere. Four weeks later, all mice were sacriﬁced and
analyzed for Fluc expression in the tissue lysate of hippocampus
and thalamus of the hemisphere receiving rAAV9.Fluc (Figures 3A
and 3C). Compared with the mice receiving only the Th injection
of rAAV9.Fluc, pre-treatment with a Th injection of scAAV9.EGFP
did not change the transduction capability of the following
rAAV9.Fluc in either brain region. In contrast, pre-immunization
with scAAV9.EGFP by IM injection signiﬁcantly reduced the trans-
duction by rAAV9.Fluc in both brain regions, in most mice to several
logs lower. These results indicate a correlation between the presence
of systemic anti-AAV9 NAb induced by IM pre-immunization and
the severely compromised brain transduction by a following direct in-
traparenchymal delivery of rAAV9. However, the IM pre-immuniza-
tion regimen could trigger pleiotropic immune responses beyond
generating circulating NAb.
Passive Transfer of NHP Serum Containing Anti-AAV9 NAb to
Mouse Does Not Compromise Intracranial Gene Delivery by
rAAV9
To further test whether the AAV9 NAb induced by the IM pre-immu-
nization regimen was the sole cause of compromised brain transduc-
tion by brain rAAV9 delivery, we performed a passive transfer exper-
iment (Figure 4A). We ﬁrst pooled three cynomolgus monkey serum
samples that were previously determined to be positive for AAV9
NAb,which allowedus to use the sameNHPserum sample of sufﬁcient
amount to pre-condition multiple mice. In the pilot experiment, we
determined that IV delivery of 200 mL of the NHP serum pool to
mice generated robust AAV9 NAb in the mouse sera (Figure 4B).
Next, we treated another batch of pre-conditioned mice or naive
mice with Th delivery of rAAV9.Fluc. Four weeks later, mice were
sacriﬁced, and we analyzed Fluc expression in the tissue lysate of hip-
pocampus, thalamus, and liver. In contrast to the pre-immunization
experiment (Figure 3C), passive transfer of AAV9 NAb-containing
NHP serum did not compromise the intracranial gene delivery by
rAAV9 (Figure 4C). In the naive mice not receiving NHP serum, the
intracranial injection also led to liver transductiondue to vector leakage
out of the CNS compartment (Figure 4C). As expected, the liver trans-
duction in the pre-conditioned mice was diminished (Figure 4C).
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(A) Experimental workflow. Wild-type C57BL/6 mice
(male, 6–8 weeks old) received either intrathalamus (Th) or
intramuscular (IM) delivery of scAAV9.EGFP as the first
injection.Mice receiving no rAAV served as naive controls.
Four weeks later, sera were collected to determine the
anti-AAV9 NAb titer. One week later, all mice received
rAAV9.Fluc by Th delivery. For the mice receiving Th de-
livery as the first injection, the second Th injection was at
the contralateral hemisphere. Four weeks after the sec-
ond injection, mice were sacrificed for gene expression
analysis. GC, Genome copies. (B) Anti-AAV9 NAb titer in
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determined by the in vitro assay. Samples are categorized
by the AAV NAb titer that is presented on a gray scale.
(C) Quantification of the firefly luciferase expressed in the
hippocampus and thalamus of the hemisphere injected
with rAAV.Fluc. Each dot represents an individual mouse.
The means and SDs of each group (n = 4–6 mice) are
shown. *p < 0.05; ns, not significant by Dunn’s test cor-
rected for multiple comparisons within each tissue group.
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DISCUSSION
The inhibitory effect of circulating AAV NAb on gene-therapy efﬁ-
cacy is evident in clinical studies. The lack of effective methods to
circumvent neutralization necessitates the exclusion of sero-positive
patients from some clinical trials. The same issue exists when per-
forming a pre-clinical toxicology study and/or gene-transfer efﬁ-
ciency study in large-animal species such as NHPs. Previous studies
surveyed NAbs against several AAV serotypes in general human pop-
ulations,5,28 speciﬁc patient populations,29–32 and several animal spe-
cies.33,34 Collectively, these studies provide a guidance for selecting
AAV serotype vectors to maximize the serologically compatible study
subjects. Here, we greatly extend this effort by reporting a large AAV
NAb dataset consisting of multiple animal species and AAV sero-
types. The vast majority of data points concern RMs and CMs, two
species commonly used in rAAV gene therapy development. These
data can be informative for the selection of AAV serotypes and animal
species for testing a gene-therapy application. For example, similar to
humans,28 RMs appear to have limited AAV5 NAb prevalence (Fig-
ure 1A), justifying their use in testing rAAV5-mediated gene transfer.
For testing applications using rAAV8, CMs may be preferred over
RMs, because AAV8 NAb is more prevalent in the latter species (Fig-
ure 1A). It should be noted that some studies may allow for NAb titers
up to a certain degree or require sero-positive subjects, such as testing
strategies to circumvent the NAb barrier. The NAb dataset reported
here will also be informative in such cases.
By comparing the results of in vitro and in vivoNAb assays for a large
number of serum samples, we conﬁrmed previous ﬁndings that both
assays can consistently distinguish sero-positive and sero-negative
subjects in most cases.10,35 However, due to the low sensitivity of
the in vitro NAb assay, it may not identify subjects that harbor low-
titer NAbs (Figure 2B). Based on this notion, themore rigorous in vivo
NAb assay was used to screen patients for the hemophilia B trial that
employed an AAV8 vector.15,16 Overall, our results support a two-
step AAV NAb screening strategy: performing the high-throughput
in vitro assay ﬁrst, followed by the in vivo assay to identify subjects
with low-titer NAbs if necessary. The unexpected discrepancy
between the two assays with marmoset and sheep sera may indicate
that the current in vitro assay may overestimate their neutralizing ef-
fects and that assay optimization is necessary. Some non-neutralizing
serum factors may exist to alter rAAV transduction. For example,
previous studies showed that certain serum factors can impact
rAAV transduction in a serotype- and species-dependent manner.34
The immune-privileged CNS compartment is not completely resis-
tant to pre-existing AAV immunity during rAAV gene delivery. Mul-
tiple routes of rAAV administration can target the CNS. Although a
convenient systemic delivery of certain AAV serotype vectors, such as
AAV9 and AAVrh.10, can transduce widespread CNS regions, this
route of administration faces the barrier of circulating NAbs and de-
mands a large quantity of vectors. Nevertheless, it is practical and
effective in treating infant patients of spinal muscular atrophy;36 chil-
dren at this age usually have limited AAV NAbs and need a relatively
small amount of rAAV due to their low body weight. rAAV delivery
to the cerebrospinal ﬂuid (CSF) is a viable option to achieve global
CNS gene transfer with a greatly reduced vector load.26 Importantly,
studies in NHPs demonstrated that intra-CSF rAAV9 delivery to
target the CNS is resistant to NAb in the bloodstream to a degree.9,20
To target CNS diseases that afﬂict a limited brain region such as
Parkinson’s disease, a direct intraparenchymal rAAV injection to
the disease foci remains an attractive approach and is under extensive
clinical evaluation,26 in part due to the robust local transduction and
very small amount of rAAV needed. Early studies mainly evaluated
AAV2 and AAV5 vectors for such applications including the impact
of anti-AAV2 and -AAV5 NAbs. These studies suggested that brain
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group (n = 6 mice) are shown. **p < 0.01; ns, not significant by non-parametric
Mann-Whitney test.
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transduction by intraparenchymal rAAV delivery can be severely
compromised in the presence of circulating NAbs.24,37 Recently, other
AAV serotype vectors were shown to more efﬁciently target CNS cells
by intraparenchymal delivery.27
To examine whether a highly CNS-tropic serotype such as AAV9may
overcome NAb, we modeled intraparenchymal rAAV9 delivery in the
presence of anti-AAV9 NAb generated by either pre-immunization
or passive transfer of NHP serum to mice. Our results showed that
circulating anti-AAV9 NAb up to 1:20–1:40 alone is not sufﬁcient
to compromise intracranial rAAV9 gene delivery. The inhibitory
effect by the pre-immunization regimen may be due to pleiotropic
immune responses induced by the IM route of administration. There-
fore, our results suggest that assaying pre-existing NAb alone may not
be informative in studies employing intraparenchymal rAAV9 injec-
tions. The effects of other aspects of pre-existing AAV immunity on
brain intraparenchymal rAAV gene delivery remain to be studied.
Notably, the immune responses triggered by natural infection and
rAAV administration are different.38 Therefore, studying the pre-
existing AAV immunity in these scenarios may provide insights for
different applications including rAAV re-administration. It will be
also informative to determine whether the NAb titer can serve as a
surrogate to gauge overall pre-existing AAV immunity and thus a
convenient marker to select proper subjects.
In summary, the large-animal AAV NAb dataset reported here may
further facilitate the selection of serotype and animal species for a
rAAV-mediated gene-transfer study. Our data suggest that the
more convenient in vitro NAb assay is sufﬁcient in most cases. The
more sensitive in vivo NAb assay may be necessary to better identify
subjects with low-titer NAbs; these subjects may not be suitable for
applications that are prone to NAbs, such as systemic rAAV delivery.
In studies involving brain intraparenchymal rAAV gene delivery,
screening for NAbs may not provide a deﬁnitive inclusion criterion.
Further studies are required to determine whether other immunolog-
ical markers can be informative and whether NAb titer can serve as a
surrogate for this purpose.
MATERIALS AND METHODS
Serum Sample Collection from Large Animals
Sera were collected from large animals by various parties, including
academic laboratories and pharmaceutical companies, shipped to
the University of Massachusetts Medical School Viral Vector Core
on dry ice and stored under 80C until assay. For conﬁdentiality
reasons, the detailed information of the donor animals was not avail-
able in most cases, such as geographic location, age, sex, and housing
conditions.
Use of Mice
WTC57BL/6male mice (6–8 weeks old) were used in all experiments.
Mice were obtained by in-house breeding and kept with a 12-hr light
cycle. Intravascular delivery was performed by tail-vein injection. Th
delivery was performed using a stereotaxic instrument (Stoelting) on
anesthetized mice. One microliter of rAAV preparation was delivered
using a 33G Hamilton syringe (model #1701, Hamilton) attached to
an automatic infusion pump over 5 min. The injection coordinates
were X = ±1.5 mm; Y = 2.0 mm (Bregma was set as X = 0, Y =
0); Z =3.5 mm (skull surface was set as Z = 0). IM delivery was per-
formed by direct injection of 10 mL of rAAV preparation into the left
tibialis anterior muscle. All animal procedures were approved by the
Institutional Animal Care and Use Committee at University of Mas-
sachusetts Medical School.
rAAV Production
All rAAV genome constructs carry the ubiquitous cytomegalovirus
enhancer-chicken beta-actin promoter driving the expression of a
transgene of human alpha-1-antitrypsin (hA1AT), EGFP, Fluc, or
b-galactosidase (LacZ). All rAAVs were generated by triple-transfec-
tion of a cis-plasmid containing the rAAV genome construct ﬂanked
by AAV2 inverted terminal repeats, a trans-plasmid containing the
AAV2 rep gene and serotype-speciﬁc cap gene, and a helper plasmid
containing certain adenovirus genes in HEK293 cells. The hA1AT,
Fluc, and LacZ vectors were packaged as single-stranded genomes,
and the EGFP vector was packaged as self-complementary genome.
rAAV particles were puriﬁed from cell lysate and culture media
by two rounds to cesium chloride sedimentation and dialysis. The
genome titer of rAAV preparation was determined by Taqman
real-time qPCR. The purity was assessed by SDS-PAGE followed by
silver staining to visualize the viral protein (VP)1, VP2, and VP3.
In Vitro AAV- NAb Assay
Serum sample was heat-inactivated under 56C for 35 min and
1:5 diluted in Dulbecco's Modiﬁed Eagle's Medium (DMEM) fol-
lowed by 2-fold serial dilutions. Each diluted serum sample was incu-
bated with 1.2 109 genome copies (GC) of rAAV.LacZ in a total vol-
ume of 120 mL DMEM under 37C/5% CO2 for 1 hr. Naive mouse
serum (Sigma-Aldrich, cat. #S-3509) was prepared in the same
manner as negative control. Huh7 cells grown in a 96-well plate
were ﬁrst infected with WT adenovirus serotype 5 (100 viral particles
per cell). Three to four hours later, 100 mL of pre-incubated rAAV-
serum mixture containing 1  109 GC of rAAV.LacZ was added to
each well of Huh7 cell culture and incubated under 37C/5% CO2
for 1 hr. Triplicate wells were included for each dilution of a sample.
Cells were then cultured with 5% fetal bovine serum under 37C/5%
CO2 overnight. b-galactosidase activity in cell lysate wasmeasured us-
ing the Galacto-Star One-Step b-galactosidase Reporter Gene Assay
System (Thermo Fisher Scientiﬁc, cat. #T1014), in which the b-galac-
tosidase activity correlates with luminescence readings. Because the
presence of mouse serum enhances the transduction of certain
AAV serotypes in a dose-dependent manner, the luminescence read-
ings from the naive mouse serum controls at each dilution were
normalized to 100%. The transduction inhibition effect of a test sam-
ple at each dilution was calculated by comparing with the naivemouse
serum control at the same dilution. The NAb titer was deﬁned as a
range between the lowest dilution factor that yielded more than
50% transduction inhibition and the next dilution factor that could
not inhibit transduction by more than 50%. For example, a serum
sample inhibited transduction by 60% at 1:5 dilution but inhibited
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transduction by only 30% at 1:10 dilution; the NAb titer was deemed
1:5–1:10. If the least diluted (1:5) serum sample could not inhibit
transduction by more than 50%, the NAb titer of the sample was
deemed <1:5. If the most diluted (1:20) serum sample could inhibit
transduction by more than 50%, the NAb titer of the sample was
deemed >1:20. Due to the limited amount of mouse serum (Figure 3),
the starting dilution was 1:10.
In Vivo AAV NAb Assay
200 mL of heat-inactivated (56C for 35min), undiluted serumwas in-
jected to each mouse through the tail vein. Either immune-compro-
mised7 or immune-competent mice10 can be used in this assay, and
we used the immune-competent C57BL/6 mice for convenience.
Three to four mice were treated for each test serum sample. Mice
receiving naive mouse serum (Sigma-Aldrich, cat. #S-3509) served
as baseline control. Two hours later, rAAV.hA1AT was injected
through the tail vein; the dose was dependent on the AAV serotype.
Two weeks later, blood was collected from the facial vein and serum
was isolated using a serum separator (BD, cat. #365967) and stored
under 80C until assay. Serum hA1AT was determined using an
enzyme-linked immunosorbent assay (ELISA). The serum hA1AT
from the mice receiving naive mouse serum was normalized to
100% in each assay, and the transduction inhibition in the presence
of passively transferred test serum was calculated and statistically
compared with the baseline control by Student’s t test.
Firefly Luciferase (Fluc) Assay
Mice were transcardially perfused with ice-cold PBS. The whole brain
was quickly dissected and cut in halves longitudinally on an ice-cold
metal block. The hippocampus and thalamus of the hemisphere
receiving rAAV9.Fluc were carefully dissected into a pre-chilled
2-mL Eppendorf tube and stored under 80C until Fluc assay.
Frozen tissue was homogenized in 200 mL of 1 Passive Lysis Buffer
(Promega, cat. #1941) with protease inhibitor (Roche, cat.
#4693159001) using TissueLyzer II (QIAGEN). Cleared lysate was
quantiﬁed for total protein concentration using the BCA assay
(Pierce, cat. #23225). Fluc activity in tissue lysate was quantiﬁed using
the Luciferase Assay System (Promega, cat. #E1501) and compared
against a standard curve generated using puriﬁed recombinant Fluc
(Promega, cat. #E1701). The amount of Fluc in tissue lysate was calcu-
lated as femtograms (fg) of Fluc per mg of total protein.
Statistical Analysis
Comparison between two groups was analyzed by Student t test (two-
tailed). Comparison among three groups was analyzed by one-way
ANOVA, and the following pairwise comparisons were corrected
for multiple comparisons. All statistical analysis was performed using
the software Prism 7.
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